Inhalation Sciences subsidiary Ziccum awarded 0.5 MSEK from Horizon 2020—the EU’s biggest Research and Innovation program

(STOCKHOLM 18-07-11) The 0.5 MSEK is to help Ziccum develop the scale-up of LaminarPace. The spray drying tool dries vaccines, peptides and biologics at room temperature—transforming them into robust, easy-to-transport dry powders. The technology could lead to the development of a new generation of novel, stable, worldwide therapies, with IP rights built on LaminarPace.

It’s the most ambitious Research and Innovation programme the EU has ever launched. Horizon 2020 draws on the expertise of international experts to identify high-potential world-firsts, and grow them from the lab to the market—growing Europe’s science and industry leadership in the process.

Ziccum has been awarded a Phase One grant. The objective is to carry out a feasibility study for an aseptic and scaled-up version of the current system for the GMP (Good Manufacturing Practise) manufacturing of pharmaceuticals. CEO Göran Conradson: "We’re well aware of how tough competition is for this funding, and how thoroughly and extensively applications are reviewed and evaluated. All projects selected in Horizon 2020 are seen as ground-breaking in their own way. We’re really proud and happy to be part of this team.”

LaminarPace: From gentleness—strength  

LaminarPace is already fully operational for small-scale applications. Horizon 2020 funding will help develop scale-up to industrial application and incorporation into client's production processes. Tests, pilots and collected feedback will validate the larger system and provide evidence to present to pharmaceutical customers and stakeholders. Göran Conradson: “As a technology, LaminarPace is all about strength—from gentleness. Developing stronger, more robust therapies from gently micronizing sensitive substances at room temperature. The new substances developed in this way could represent a whole new generation of therapies, generic and novel, all stronger, more active and more cost-effective, from the gentlest and most efficient of formulations.”

Ziccum AB, a subsidiary of Inhalation Sciences, aims to be listed in a formal IPO in Q4 2018.

For more information about Inhalation Sciences please contact:

Lena Heffler, CEO 
Email: lena.heffler@inhalation.se
Phone: +46 (0)70 205 96 20

About Inhalations Sciences Sweden AB (publ)

Inhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments for research into inhalation. The company’s patented lab instrument, PreciseInhale®, enables researchers to characterize, with high precision, how aerosols and small particles impact our lungs, and so our health, when we breathe them in.

The information above was provided by Inhalation Sciences Sweden AB (publ) according to EU Market Abuse Regulations. The information was provided, through the above contact person, for publication on July 10, 2018.

About Us

Inhalation Sciences Sweden AB (publ.) develops and sells patented, highly innovative labtech equipment for inhalation research. Scientists using it can now know, with unprecedented accuracy, how particles behave in our lungs when we inhale them: whether new pollutants or life-saving drugs that power human development.

Subscribe

Documents & Links